Bio-Techne Corp

Valuation Analysis

About the Company

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifyi

Bio-Techne Corp Stock at a Glance

Bio-Techne Corp (TECH) is currently trading at $54.00 with a market capitalization of $8.5B. The trailing P/E ratio stands at 77.14x, with a forward P/E of 26.27x. The 52-week range spans from $43.20 to $72.16; the current price is 25.2% below the yearly high. Year-over-year revenue growth stands at -1.5%. The net profit margin stands at 9.05%.

💰 Dividend

Bio-Techne Corp pays an annual dividend of $0.32 per share, representing a yield of 0.59%. The payout ratio stands at 45.71%.

📊 Analyst Rating

13 analysts rate Bio-Techne Corp (TECH) on consensus: Buy. The average price target is $61.69, implying +14.25% from the current price. Analyst price targets range from $49.00 to $75.00.

Bio-Techne Corp: The Investment Case in Detail

Bio-Techne Corp (TECH) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Earnings growth of 128.6% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. With a gross margin near 66.4%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.

The Bear Case

Revenue is contracting at -1.5% year-over-year — until that trend reverses, valuation is exposed to further downgrades. A trailing P/E above 50 combined with revenue growth below 20% is a dangerous combination — the market is paying a steep growth multiple for what is, by the data, only moderately fast expansion. Short interest sits at 10.09% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valuation in Context

With a PEG ratio of 0.74, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.

What to Watch Next

• The forward P/E of 26.27x is meaningfully below the trailing 77.14x — analysts expect earnings to step up; the next earnings release is the test.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

The price is in a transition zone relative to the moving averages — no clear signal.

Risk Profile

The data points to market-like volatility, elevated short interest (10.09%).

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Bio-Techne Corp?

Compare top-rated brokers — low fees, trusted providers, fully regulated.